|
|
Geographic Atrophy Secondary to Age-Related Macular Degeneration: Innovative Therapies for Sight Revival
Multimodal imaging is key for the early detection and monitoring of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Optical coherence tomography has recently been recommended by an international consensus to be the primary imaging method for the detection of atrophy in eyes. Once diagnosed, timely therapeutic intervention should be initiated with recently FDA-approved therapies that target components of the complement cascade. When optimally integrated into persona... |
|
|
Mastering Treatment-Naive nAMD
In this Master Class case, Dr. Priya Vakharia discusses the management of a 72-year-old White man with treatment-naive neovascular age-related macular degeneration. |
|
|
Mastering Suboptimal Treatment Response in nAMD
In this Master Class case, Dr. David Eichenbaum discusses the management of a 69-year-old White man with neovascular age-related macular degeneration who receives a suboptimal treatment response to initial anti-vascular epithelial growth factor therapy. |
|
|
Mastering Treatment-Refractory nAMD
In this Master Class case, Dr. Michael Singer discusses the management of an 82-year-old Hispanic man with treatment-refractory neovascular age-related macular degeneration. |
|
|
Mastering Treatment-Naive DME
In this Master Class case, Dr. Mark R. Barakat discusses the management of a 76-year-old White man with treatment-naive diabetic macular edema. |
|
|
Mastering Suboptimal Treatment Response in DME
In this Master Class case, Dr. W. Lloyd Clark discusses the management of a 75-year-old Black woman with diabetic macular edema who has a suboptimal treatment response to initial anti-vascular epithelial growth factor therapy. |
|
|
Mastering Treatment-Refractory DME
In this Master Class case, Dr. Diana Do discusses the management of a 58-year-old White woman with treatment-refractory diabetic macular edema. |
|
|
Inherited Retinal Diseases: Navigating the Future of Diagnostics and Emerging Therapies
The differential diagnosis and workup of a suspected inherited retinal disease (IRD) can be challenging, requiring the expertise of the multidisciplinary healthcare team. Guidelines released in 2022 by the American Academy of Ophthalmology provide recommendations and clinical genetic assessments for patients with IRDs. Genetic counseling is essential to help patients understand the genetic test results, their implications for prognosis, family planning, and therapeutic decisions. Genetic testi... |
|
|
nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
Frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies can significantly improve visual and anatomical outcomes for many patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the requisite high number of treatments often leads to less-than-ideal results compared to outcomes reported in major clinical trials, largely due to the demanding treatment schedule. Adopting tailored treatment plans, along with ... |
|
|
Thyroid Eye Disease: Unmasking and Taming What’s in Disguise
Thyroid eye disease (TED) is a complex autoimmune-mediated inflammatory disorder of the orbit that is associated with a spectrum of signs and symptoms and varying levels of severity. Early diagnosis and initiation of appropriate treatment are imperative for preventing progression to severe disease and potential vision loss. However, diagnosis can be challenging. Traditional treatments for TED, such as steroids, radiotherapy, and surgery, all relieve symptoms but do not alter the course of dise... |
|
|
Solving the TED Puzzle: Answering Your Questions on Diagnosis to Decision-Making
Thyroid eye disease (TED) is a complex, autoimmune-mediated, inflammatory disorder of the orbit that presents with a range of symptoms, including ocular pain, dysmotility, and changes in ocular structure and function. The disease severely impacts patients' quality of life, often resulting in persistent discomfort, altered appearance, and impaired vision even after the acute phase subsides. Traditional treatments such as steroids, radiotherapy, and surgery, do not alter the disease's ... |
|
|
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to exte... |
|
|
Nutraceuticals for Dry Eye: Dispelling the Dogma and Embracing the Data
Dry eye disease is a common yet frequently overlooked condition that significantly affects quality of life. Despite an estimated global prevalence of up to 50%, DED is often underdiagnosed and inadequately managed. To limit the burden of DED, it is crucial for clinicians to be adept at recognizing risk factors and making accurate diagnoses. In addition, as treatment options expand to include clinically proven nutraceuticals, it is imperative that clinicians stay abreast of the latest clinical ... |
|
|
Patient‐Centered GA Care: A Synergistic Approach to Optimize Management
The recent FDA approval of 2 novel therapies for the management of patients with geographic atrophy (GA) secondary to age-related macular degeneration has further reenforced the necessity for early GA diagnosis to limit progression. Advances in imaging technologies now provide tools for better detection and characterization of GA, along with biomarkers to monitor progression over time. Optometrists, as front-line eye healthcare providers, play a critical role in the timely diagnosis, managemen... |
|
|
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy, and geographic atrophy (GA) secondary to... |
|
|
GA and Advances in Imaging and Surgery: State-of-the-Art Management
The continued evolution of diagnostic, therapeutic, and surgical algorithms for the management of patients with retinal diseases offer the potential for enhancing visual, anatomical, and quality-of-life outcomes in these patients. Recognition, understanding, and application of these evidence-based advances are imperative to enhance treatment outcomes and patient satisfaction. During Part 2 of this 2-part educational activity, updates in geographic atrophy will be discussed, along with advances... |
|
|
nAMD, Diabetic Eye Disease, and RVO: State-of-the-Art Management
The continued evolution of diagnostic, therapeutic, and surgical algorithms for the management of patients with retinal diseases offer the potential for enhancing visual, anatomical, and quality-of-life outcomes in these patients. Recognition, understanding, and application of these evidence-based advances are imperative to enhance treatment outcomes and patient satisfaction. During Part 1 of this 2-part educational activity, updates in state-of-the-art management strategies for neovascular ag... |
|
|
Neurotrophic Keratitis: Old Problem, New Solutions
Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments. |
|